Skip to content Skip to footer
Subscribe Now
NEWS

Formosa Pharmaceuticals Collaborates with Rxilient to Commercialize APP13007 Across ASEAN Markets

Shots: Formosa has entered into an exclusive licensing agreement with Rxilient to commercialize APP13007, a 0.05% clobetasol propionate ophthalmic suspension for the treatment of inflammation & pain after ocular surgery As per the deal, Rxilient will gain exclusive rights to commercialize the suspension across key ASEAN markets, incl. Indonesia, Philippines, Singapore, & Thailand, with the deal…
December 3, 2025

Read more

Formosa Pharmaceuticals
NEWS

Formosa Pharmaceuticals Receives the US FDA’s Approval for Clobetasol Propionate to Treat Post-Operative Inflammation and Pain Following Ocular Surgery 

Shots:  The US FDA has approved Formosa’s clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat post-operative inflammation & pain following ocular surgery  Sosei Heptares will receive a payment of $2.5M from Formosa on achieving the milestone as per the agreement signed b/w them  APP13007 was initially developed by Activus Pharma (subsidiary of Sosei) using its…
March 4, 2024

Read more